Functional Status in Patients With Cancer: A Comparative Analysis of ECOG and Karnofsky Performance Status Scales, Geriatric Assessment, and Clinical Use

Assessment of a patient’s overall clinical condition is a key component of decision-making in modern oncology practice. As treatment options continue to expand, including targeted therapy, immunotherapy, and combination treatment regimens, individualized patient management is becoming increasingly important. In this context, functional status is considered one of the most important factors determining treatment tolerability, the risk of complications, and disease prognosis.

Unlike traditional parameters, such as tumor stage and the molecular genetic characteristics of the neoplasm, functional status reflects the patient’s overall ability to adapt to the stress associated with both the disease and its treatment. For this reason, standardized assessment of the patient’s general condition is an essential part of clinical evaluation.

This article reviews the main scales used to assess functional status, including ECOG Performance Status and Karnofsky Performance Status, as well as additional geriatric assessment tools. Their clinical significance and role in personalizing cancer treatment are also discussed.

Clinical Significance of Assessing the Overall Condition of Patients With Cancer

Assessment of the patient’s overall condition is an important element of clinical decision-making in modern oncology. Along with disease stage, tumor morphology, and the molecular genetic features of the tumor, the patient’s functional status determines whether different types of cancer treatment can be used and helps estimate disease prognosis.

Functional status reflects the patient’s ability to perform everyday physical activity, remain independent in activities of daily living, and tolerate the burden associated with cancer therapy. In patients with cancer, deterioration in overall condition may result from tumor progression, comorbidities, cachexia, age-related changes, or treatment-related toxicity. Therefore, objective assessment of functional status is an essential part of clinical evaluation.

Numerous studies show that functional status is an independent prognostic factor for overall survival and tolerability of cancer therapy. Patients with preserved functional status are more likely to receive combination or intensive treatment and tend to have better treatment outcomes. In contrast, patients with marked functional limitations have a higher risk of treatment-related toxicity, dose reductions, and premature treatment discontinuation.

Assessment of overall condition is also used when clinical trials are planned. Functional status is one of the main eligibility criteria and helps ensure comparability between study groups. In addition, dynamic monitoring of functional status helps identify clinical deterioration in a timely manner and adjust the treatment strategy when needed.

Current clinical guidelines from the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the American Society of Clinical Oncology emphasize the need to assess functional status before initiating systemic therapy. This parameter is used to select treatment intensity, predict tolerability, and determine the optimal therapeutic strategy.

Thus, standardized assessment of the patient’s overall condition is an important part of comprehensive cancer care and helps improve the safety and effectiveness of treatment.

ECOG Performance Status

One of the most widely used tools for assessing functional status in patients with cancer is ECOG Performance Status. It was developed by the Eastern Cooperative Oncology Group in 1960 and is now used both in routine clinical practice and in clinical trials. Its simplicity, reproducibility, and strong prognostic value have made ECOG Performance Status one of the standard methods for assessing the overall condition of patients with malignant tumors.

ECOG Performance Status is based on the patient’s level of physical activity and ability to perform everyday activities. Unlike more detailed scales, it uses a limited number of categories, which makes it easier to apply in clinical practice. The assessment is performed by a physician based on clinical interview, observation, and evaluation of the patient’s ability to perform self-care and physical activity.

The scale includes six categories, from 0 to 5, reflecting the degree of functional limitation. A score of 0 corresponds to fully preserved activity, whereas higher scores reflect progressive decline in functional status. The maximum score, 5, corresponds to death.

ECOG Performance Status Criteria

The clinical significance of ECOG Performance Status lies in its strong prognostic value. Numerous studies have shown that ECOG Performance Status is an independent prognostic factor for overall survival across different types of malignant tumors. Patients with ECOG 0–1 generally tolerate intensive systemic therapy better and demonstrate greater treatment effectiveness. In contrast, patients with ECOG ≥ 3 have a significantly higher risk of treatment-related toxicity and complications.

In modern clinical practice, ECOG Performance Status is used to determine whether different types of cancer therapy can be prescribed. Threshold ECOG values are routinely considered when selecting a treatment strategy. For example, an ECOG score of ≥ 2 requires caution when cytotoxic chemotherapy is prescribed and calls for individualization of the treatment regimen. Patients with ECOG ≥ 3 are generally considered primarily for symptomatic or palliative treatment, except in selected clinical situations.

ECOG Performance Status is also widely used in the design and interpretation of clinical trials. In most randomized studies, functional status is one of the key criteria for patient inclusion and stratification. This helps ensure comparability between study groups and allows the effectiveness of new treatments to be assessed appropriately.

Despite its widespread use, ECOG Performance Status has several limitations. The main limitation is a degree of subjectivity, as the score depends substantially on the physician’s clinical experience and interpretation of the patient’s functional abilities. In addition, the scale has a relatively small number of categories, which may limit its sensitivity during dynamic follow-up.

Nevertheless, because of its simplicity and high clinical relevance, ECOG Performance Status remains one of the most important tools for assessing functional status in oncology. It standardizes assessment of the patient’s overall condition, facilitates communication between specialists, and serves as an important reference point when selecting treatment strategy.

Karnofsky Performance Status

Karnofsky Performance Status (KPS) is a classic tool for assessing functional status in patients with cancer. It was developed in 1948. The scale provides a quantitative assessment of the patient’s ability to function independently and tolerate treatment, helping predict treatment outcomes and survival. KPS ranges from 100, meaning fully active and without limitations, to 0, meaning death, in 10-point increments that reflect progressive decline in functional status.

Karnofsky Performance Status (KPS)

KPS is used to stratify patients in clinical trials and to assess indications for chemotherapy, radiation therapy, and surgical interventions. Higher scores, typically 80–100, are usually associated with good tolerability of aggressive treatment regimens. Low scores, especially < 50, indicate the need for a palliative approach or dose modification. The key advantage of the scale is its greater level of detail compared with ECOG, which allows more precise monitoring of changes in the patient’s condition and helps predict the risk of toxicity.

Current studies confirm the prognostic value of KPS. It correlates with overall survival in solid tumors and hematologic malignancies, as well as with the likelihood of achieving an objective response to treatment. KPS is often used together with other scales and biomarkers as part of a comprehensive patient assessment, including comorbidity indices, laboratory parameters, and patient-reported outcomes (PROs).

However, the scale also has limitations. These include subjectivity of assessment, possible differences between physicians’ ratings, known as interobserver variability, and limited sensitivity to changes in cognitive and emotional domains. To improve accuracy, functional status should be assessed at several levels by combining KPS with ECOG and specialized quality-of-life scales.

Thus, KPS remains an important tool in personalized oncology practice. It provides a quantitative and reproducible assessment of functional status, which is needed for treatment selection and prediction of treatment outcomes.

Comparative Analysis of the ECOG and Karnofsky Scales

Additional Scales for Assessing Functional and Geriatric Status

In addition to ECOG and KPS, specialized scales for assessing functional status and geriatric risk are actively used in clinical practice for patients with cancer. Their use is particularly important when managing older patients, patients with multiple comorbidities, and patients being considered for intensive therapy.

Barthel Index

The Barthel Index assesses the patient’s ability to perform basic activities of daily living (ADL), such as feeding, mobility, hygiene, and bladder and bowel control. Scores range from 0 to 100, with a higher score indicating greater independence. This tool helps identify patients in whom standard chemotherapy may be excessively toxic.

Barthel Index Scale (ADL)

Total score: 0–100, where 100 indicates complete patient independence.

Lawton Scale

The Lawton Instrumental Activities of Daily Living scale, or Lawton IADL scale, focuses on more complex functional skills, including managing finances, preparing meals, using transportation, and taking medications. IADL helps predict the patient’s independence and assess the need for social support.

Lawton Scale (IADL)

Comprehensive Geriatric Assessment

Comprehensive geriatric assessment (CGA), also referred to as geriatric assessment (GA), is a multidimensional set of geriatric tools. It includes cognitive testing with the Mini-Mental State Examination (MMSE), assessment of emotional status with the Geriatric Depression Scale (GDS), nutritional assessment with the Mini Nutritional Assessment (MNA), evaluation of multimorbidity, and assessment of fall risk. CGA is critically important for stratifying older patients and selecting treatment regimens based on expected tolerability.

Comprehensive Geriatric Assessment (CGA)

Role of Frailty and PROs in Status Assessment

In modern oncology, the concept of frailty is becoming increasingly important. Frailty reflects reduced physiologic reserve and increased vulnerability to stressors. Assessment of frailty allows treatment tolerability and the risk of complications to be predicted more accurately than chronological age alone. This is essential when selecting the treatment strategy. In recent years, patient-reported outcomes (PROs) have also become increasingly important. PROs reflect the patient’s subjective perception of functional status, symptoms, and quality of life. Integrating PROs into clinical practice makes it possible to assess the impact of the disease and treatment on the patient more fully and to improve the accuracy of clinical decisions.

Studies show that integrating these scales into clinical practice improves prediction of toxicity, reduces the risk of hospitalization, and helps optimize treatment dose without loss of efficacy. Current NCCN and SIOG guidelines recommend mandatory use of comprehensive geriatric assessment in patients older than 70 years or when treatment tolerability is uncertain.

These tools complement ECOG and KPS by creating a comprehensive picture of the patient’s functional status and forming the basis for personalized treatment selection.

Find more scientifically accurate content on our social media

Subscribe and don’t miss out the latest resources

Personalizing Treatment in Patients With Cancer Based on Functional Status

Assessment of functional status is an integral part of comprehensive management of patients with cancer and plays a key role in selecting the optimal treatment strategy. The use of standardized scales, such as ECOG and Karnofsky Performance Status, helps make clinical assessment of the patient’s condition more objective, predict treatment tolerability, and stratify the risk of complications.

Additional tools, including activities-of-daily-living scales and comprehensive geriatric assessment, expand the clinician’s ability to evaluate patients, especially older adults and those with comorbid conditions. Integrating these approaches into clinical practice supports more precise treatment personalization and improves outcomes.

The further development of oncology is associated with the implementation of multidisciplinary assessment models, including PROs and digital monitoring tools. These approaches will help improve prognostic accuracy and the safety of cancer therapy.